Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

UnitedHealth's dip offers long-term value, backed by strong fundamentals, rising dividends, and growth potential. Learn why ...

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

Shares of Rivian Automotive (NASDAQ:RIVN) lost more than 6% over the past five trading days, marking the end of a rally that saw the stock gain ... are designed for performance upgrades while ...

Berkshire Hathaway is highly regarded for its financial performance and investment choices. Under Buffett (and Charlie Munger, until his 2023 death), Berkshire has grown significantly. It was the ...

It was delisted from the New York Stock Exchange in 2021 as a result of U.S. sanctions against China. Enbridge is a Canadian energy delivery company. It operates the longest and most complex oil ...